SCHEMBL116723

SCHEMBL116723

O=S(=O)(OCCF)C(F)(F)F

nearest known ligand 0.43

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CA2 P00918 7/20 0.43
CA1 P00915 6/20 0.43
CA9 Q16790 1/20 0.32
CA7 P43166 1/20 0.30
CA13 Q8N1Q1 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1032931 0.86 CA2 (0.47) CA2CA1CA9CA7CA13
SCHEMBL2013370 0.85 CA2 (0.41) CA2CA1CA9CA7
SCHEMBL15282824 0.82 CA2 (0.46) CA2CA1CA9CA7CA13
SCHEMBL1759312 0.82 CA2 (0.42) CA2CA1CA9
SCHEMBL575713 0.81 CA2 (0.44) CA2CA1CA9CA7
SCHEMBL576009 0.81 CA2 (0.44) CA2CA1CA9CA7CA13
Ammonia Solution, Strong SCHEMBL28986366 0.80 CA2 (0.41) CA2CA1CA9
SCHEMBL23291930 0.79 CA2 (0.46) CA2CA1CA9CA7
SCHEMBL1759310 0.79 CA2 (0.43) CA2CA1CA9CA7CA13
SCHEMBL4952312 0.79 CA2 (0.46) CA2CA1CA9CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 223 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107275675-A A kind of nonaqueous lithium ion battery electrolyte and lithium ion battery 珠海市赛纬电子材料股份有限公司 2017-10-20 CN claimed
US-8940793-B2 4-[(haloalkyl)(dimethyl)ammonio]butanoates and use thereof in the treatment of cardiovascular disease JSC GRINDEKS (LV) 2015-01-27 US claimed
US-20140107202-A1 4-[(haloalkyl)(dimethyl)ammonio]butanoates and use thereof in the treatment of cardiovascular disease JSC GRINDEKS (LV) 2014-04-17 US claimed
EP-2702037-A1 4-[(HALOALKYL)(DIMETHYL)AMMONIO]BUTANOATES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISEASE Grindeks, A Joint Stock Company (LV) 2014-03-05 EP claimed
WO-2012146737-A1 4-[(HALOALKYL)(DIMETHYL)AMMONIO]BUTANOATES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISEASE GRINDEKS, A JOINT STOCK COMPANY (LV) 2012-11-01 WO claimed
US-12630516-B2 Compounds NRG THERAPEUTICS LTD. (GB) 2026-05-19 US disclosed
EP-4667056-A1 IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF Gilead Sciences, Inc. (US) 2025-12-24 EP disclosed
EP-4208442-B1 MPTP INHIBITORS NRG THERAPEUTICS LTD (GB) 2025-10-22 EP disclosed
US-20250179028-A1 ACRYLAMIDE COMPOUNDS NRG THERAPEUTICS LTD (GB) 2025-06-05 US disclosed
EP-4486721-A1 ACRYLAMIDE COMPOUNDS NRG Therapeutics LTD (GB) 2025-01-08 EP disclosed
US-20240360114-A1 FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF Sironax Ltd. (KY) 2024-10-31 US disclosed
US-12122764-B2 IKAROS zinc finger family degraders and uses thereof GILEAD SCIENCES, INC. (US) 2024-10-22 US disclosed
WO-2002102250-A1 $G(IN VIVO) IMAGING GLAXO GROUP LIMITED (GB) 2002-12-27 WO disclosed
EP-1022279-B1 NEW CARBAPENEM DERIVATIVES MEIJI SEIKA KAISHA (JP) 2002-09-04 EP disclosed
CN-1081641-C Carbapenem derivatives and antimicrobials MEIJI SEIKA KAISHA (JP) 2002-03-27 CN disclosed
US-6180622-B1 ANTIMICROBIAL ACTIVITY AGAINST A WIDE RANGE OF BACTERIA INCLUDING GRAM-POSITIVE BACTERIA, GRAM-NEGATIVE BACTERIA, BETA-LACTAMASE-PRODUCING BACTERIA, RESISTANT PSEUDOMONAS AERUGINOSA,METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS AND MEIJI SEIKA KAISHA, LTD. (JP) 2001-01-30 US disclosed
EP-1022279-A1 NEW CARBAPENEM DERIVATIVES MEIJI SEIKA KAISHA LTD. (JP) 2000-07-26 EP disclosed
CN-1244868-A Novel carbapenem derivative MEIJI SEIKA KAISHA (JP) 2000-02-16 CN disclosed
CN-1209810-A Carbapenem derivative and antibacterial agent MEIJI SEIKA KAISHA (JP) 1999-03-03 CN disclosed
EP-0887352-A1 CARBAPENEM DERIVATIVES AND ANTIMICROBIALS MEIJI SEIKA KAISHA LTD. (JP) 1998-12-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12630516-B2 Compounds CYP4B1, CYP1B1, NR4A1 CA2 1919/4885CA1 754/4885CA9 920/4885
US-20140107202-A1 4-[(haloalkyl)(dimethyl)ammonio]butanoates and use thereof in the treatment of cardiovascular disease FABP3, HCN3, HCN4 CA2 704/4885CA1 997/4885CA9 1240/4885
US-20240360114-A1 FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF AIFM2, GPX1, GPX4 CA2 2405/4885CA1 3220/4885CA9 3943/4885
US-20250179028-A1 ACRYLAMIDE COMPOUNDS ACR, CCNI, FANCI CA2 1928/4885CA1 661/4885CA9 1070/4885
US-12122764-B2 IKAROS zinc finger family degraders and uses thereof IKZF2, IKZF1, IKZF3 CA2 3263/4885CA1 3665/4885CA9 4415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.